Michael Zelefsky, MD
Radiation Oncology · New York, NYNPI 1093785065
Payments from drug & device makers
Across 285 payments — averaging $5312.15 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Stryker$554K
- Bayer$521K
- Boston Scientific$353K
- Ferring Pharmaceuticals Inc.$51K
- Augmenix, Inc.$22K
- Angiodynamics, Inc.$4K
- plus $9K from 7 others
What the payments were for
- Consulting fees$192,70620%
- Speaking & faculty fees$694,50373%
- Travel & lodging$17,3752%
- Food & beverage$5,1311%
- Ownership interest$14,2292%
- Other$21,9232%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Stryker | 1 | $554,389 |
| Bayer | 3 | $520,979 |
| Boston Scientific | 269 | $353,360 |
| Ferring Pharmaceuticals Inc. | 1 | $50,715 |
| Augmenix, Inc. | 2 | $21,750 |
| Angiodynamics, Inc. | 1 | $3,500 |
| Recordati_rare_diseases_inc. | 1 | $3,000 |
| Tolmar, Inc. | 2 | $3,000 |
| Elekta, Inc. | 1 | $1,500 |
| Accuray Incorporated | 1 | $1,300 |
| Sanofi | 1 | $350 |
| Palette Life Sciences, Inc. | 1 | $99 |
| Johnson & Johnson | 1 | $19 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- SpaceOAR System$95,295
- SpaceOAR VUE System - 10mL$75,392
- GENERAL BPH$64,033
- GENERAL - THERAPIES$59,215
- SPACEOAR$38,995
- SPACEOAR VUE$18,483
- GENERAL VASCULAR ACCESS$10,725
- CLINICAL TRIAL PRODUCT$5,225
- Xofigo$3,600
- Sylvant$3,000
- ELEKTA UNITY$1,500
- CyberKnife System$1,300
- GENERAL KIDNEY STONE DISEASE$962
- JEVTANA$350
- GENERAL ONCOLOGY$156
How this compares
$1,513,962 in reported general payments places this provider in the 95th percentile of 397 radiation oncology providers in New York.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Other radiation oncology in New York
- Narek ShaverdianNew York$9.8M
- Timothy ChanNew York$3.8M
- Brandon ImberNew York$2.8M
- Silvia FormentiNew York$2.7M
- Christopher BarkerNew York$2.5M
- Eileen ConnollyNew York$1.1M
- Jonathan YangNew York$946K
- Nancy LeeNew York$914K
- Benjamin CooperNew York$800K
- Catherine SpinaNew York$618K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.